– Company updates that F-18 fluciclovine (Axumin®) PET/CT now listed in American College of Radiology Appropriateness Criteria® for the Post-Treatment Follow-up of Prostate Cancer – BURLINGTON, Mass. and OXFORD,...Read More ›
Welcome to Blue Earth Diagnostics
Our mission is to transform the clinical management of patients with cancer by developing and delivering innovative molecular imaging technologies to address unmet clinical needs, and reliably inform diagnosis and treatment decisions.
Our team is made up of industry leaders and experts in the field of radiopharmaceutical development and commercialisation.
Blue Earth Diagnostics is backed by Syncona Limited, a leading FTSE250 healthcare company focused on investing in and building global leaders in life science.